



PATENT

Docket No. 2016-4010US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Jason D. Bannan et al.
Serial No. : 09/335,581 Group Art Unit: 1645
Filed : June 18, 1999 Examiner: N.M. Minnifield
For : PEPTIDES USEFUL FOR REDUCING SYMPTOMS OF TOXIC SHOCK
SYNDROME AND SEPTIC SHOCK

AMENDMENT FEE TRANSMITTAL

ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

Sir:

Transmitted herewith is an Amendment Pursuant to 37 C.F.R. 1.111 for the above-identified application.

☒ [X] No additional fee is required.

☐ [] The additional fee has been calculated as shown below:

CLAIMS AS AMENDED

	Claims Remaining After Amendment		Highest No. Covered by Previous Payments	Present Extra	Rate	Additional Fee
Total* Claims	36	-	76	= 0	x \$18.00	\$ <u>- 0 -</u>
Independent Claims	4	-	13	= 0	x \$80.00	\$ <u>- 0 -</u>
Multiple Dependent Claim(s)	(If claims added by amendment include Multiple Dependent Claim(s) and there was not Multiple Dependent Claims(s) in application before amendment add \$260.00 to additional fee.)					\$ <u>- 0 -</u>
	Total:					\$ <u>- 0 -</u>

☐ [] Statement of "Small Entity" Status Under 37 CFR § 1.27 filed _____.
Reduced Fees Under 37 CFR § 1.9(f) (50% of total) paid herewith. \$ _____.

* Includes all independent and single dependent claims and all claims referred to in multiple dependent claims. See 37 C.F.R. § 1.75(c).

- ☐ Charge fee to Deposit Account No. 13-4500. Order No. _____.
A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- ☒ The Assistant Commissioner is hereby authorized to charge any additional fees which may be required for this amendment, including all fees pursuant to 37 C.F.R. § 1.17 for its timely consideration, or credit any overpayment to Deposit Account No. 13-4500. Order No. 2016-4010US2.
A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- ☐ ____ Page(s) of substitute Sequence Listing
- ☐ ____ Computer disk(s) containing substitute Sequence Listing
- ☐ Statement under 37 C.F.R. § 1.825(b) that the computer and paper copies of the substitute Sequence Listing are the same.
- ☐ A check in the amount of \$ _____ to cover the filing fee is attached.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: October 12, 2000


By: _____

Mary J. Morry
Mary J. Morry
Registration No. 34,398

CORRESPONDENCE ADDRESS:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, New York 10154
(212) 758-4800
(212) 751-6849 Facsimile

FORM: AMD-TRAN.NY
Rev. 11/13/98



Docket No. 2016-4010US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Jason D. Bannan et al.
Serial No. : 09/335,581 Group Art Unit: 1645
Filed : June 18, 1999 Examiner: N.M. Minnifield
For : PEPTIDES USEFUL FOR REDUCING SYMPTOMS OF TOXIC
SHOCK SYNDROME AND SEPTIC SHOCK

F. Tuck
8/2
10/24/00

AMENDMENT UNDER 37 CFR §1.111
IN RESPONSE TO RESTRICTION/ELECTION REQUIREMENT

Assistant Commissioner of Patents
Washington, D.C. 20231

Dear Sir:

This is in response to the Office Action mailed September 12, 2000 subjecting the pending claims to a restriction/election requirement.

AMENDMENTS

Please amend the inventorship designation to delete Kumar Visvanathan as a named inventor.

Please cancel claims 4 to 6, 8 and 11 to 49 without prejudice.

Please add the following new claims:

50. A peptide comprising a consensus amino acid sequence CMYGGX₁TX₂HX₄GN (SEQ ID NO: 30) wherein X₁ is selected from the group consisting of V and I; X₂ is selected from the group consisting of L, E, K, P and N and wherein X₄ is selected from the group consisting of D, N, E, Q and H.

51. A peptide of claim 50 wherein X₁ is V.